| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/DME.12627 |
| P698 | PubMed publication ID | 25472014 |
| P2093 | author name string | R E J Ryder | |
| P2860 | cites work | A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? | Q36942123 |
| Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
| The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits | Q38145277 | ||
| Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 | ||
| Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | Q43254579 | ||
| Incretins and pancreatitis--what happens next? A personal viewpoint | Q45342248 | ||
| Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. | Q51468997 | ||
| Bladder cancer risk and personal hair dye use. | Q53370388 | ||
| Body mass index, physical activity, and bladder cancer in a large prospective study. | Q53540020 | ||
| Does diabetes therapy influence the risk of cancer? | Q54732953 | ||
| Thiazolidinediones and Heart Failure: A teleo-analysis | Q57413498 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). | Q31120403 | ||
| Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats | Q33800079 | ||
| Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. | Q34086275 | ||
| A practical guide to basal and prandial insulin therapy. | Q34562788 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study | Q34623719 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 | ||
| Diabetes and risk of bladder cancer: evidence from a case-control study in New England | Q35051024 | ||
| Hair dye use and risk of bladder cancer in the New England bladder cancer study | Q35464023 | ||
| Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Association between smoking and risk of bladder cancer among men and women | Q36231850 | ||
| Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 305-313 | |
| P577 | publication date | 2014-12-03 | |
| P1433 | published in | Diabetic Medicine | Q15758639 |
| P1476 | title | Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit | |
| P478 | volume | 32 |
| Q47849041 | Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? |
| Q38933618 | Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review |
| Q92418413 | Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
| Q46603087 | Genotoxic investigation of a thiazolidinedione PPARγ agonist using the in vitro micronucleus test and the in vivo homozygotization assay |
| Q37355883 | Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study |
| Q33792375 | Management of diabetes mellitus in patients with chronic kidney disease |
| Q46294347 | Pioglitazone ameliorates methotrexate-induced renal endothelial dysfunction via amending detrimental changes in some antioxidant parameters, systemic cytokines and Fas production |
| Q89569320 | Reducing the burden of diabetes treatment: A review of low-cost oral hypoglycemic medications |
| Q26782232 | Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism |
| Q36581133 | Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. |
Search more.